Security
Inhibikase Therapeutics, Inc. Common Stock · IKT
IKTNASDAQCommon stockCurrentCIK 1750149Updated Oct 22, 2026
IKT price & chart
Loading TradingView…
NASDAQ:IKT on TradingView ↗About the company
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enro…
In the news
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT) News provided by Purcell & Lefkowitz LLP May 05, 2025, 08:30 ET Share this article Share to X Share this article Share to X NEW YORK , May 5, 2025 /PRNewswire/ -- Purcell & L ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Changes in Registrant's Certifying Accountant
Items 4.01, 9.01
SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding Inhibikase Therapeutics, Inc.
SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding Inhibikase Therapeutics, Inc.
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 79,594,541Source | 4,376,875Source | 163,588,612Source | 88,853,230Source | 8,826,798Source | 173,332,227Source | 94,281,322Source | 11,068,098Source | 181,204,516Source | 98,599,846Source | 14,506,647Source | 24,936,297Source |
| Property, Plant and Equipment, NetUSD | 0Source | 53,667Source | — | 23,687Source | 60,235Source | — | 47,845Source | 66,804Source | 0Source | 47,100Source | 73,372Source | 236,532Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | — | — | — | — | — | 178,800,000Source | 56,500,000Source | 9,170,000Source | 7,190,000Source |
| Assets, CurrentUSD | 78,536,628Source | 4,190,103Source | 162,343,915Source | 88,794,625Source | 8,602,801Source | 172,176,468Source | 94,164,758Source | 10,807,834Source | 180,109,395Source | 98,451,309Source | 14,211,048Source | 24,371,122Source |
| Prepaid Expense and Other Assets, CurrentUSD | 618,783Source | 280,914Source | 933,938Source | 682,628Source | 356,487Source | 1,292,813Source | 931,992Source | 851,057Source | 343,374Source | 826,473Source | 739,179Source | 163,452Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 133,105Source | — | 34,918Source | 163,762Source | — | 68,719Source | 193,460Source | 0Source | 101,437Source | 222,227Source | 328,643Source |
| Other Assets, NoncurrentUSD | 57,913Source | — | 244,697Source | — | — | 155,759Source | — | — | 95,121Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 6,696,243Source | 4,907,466Source | 10,260,026Source | 8,799,545Source | 3,730,149Source | 5,711,959Source | 8,550,650Source | 4,291,447Source | 8,300,837Source | 3,733,566Source | 3,528,725Source | 3,900,896Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 74,808Source | 7,464Source | 132,032Source | 74,516Source | 7,216Source | 132,032Source | 74,341Source | 6,477Source | 131,691Source | 69,362Source | 6,186Source | 25,227Source |
| Retained Earnings (Accumulated Deficit)USD | -129,945,149Source | -82,288,034Source | -178,651,871Source | -118,014,869Source | -76,509,968Source | -159,060,640Source | -108,099,346Source | -71,550,360Source | -142,679,800Source | -94,420,611Source | -66,900,725Source | -47,871,842Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -4,189Source | 1,754Source | -72,754Source | -2,944Source | -1,024Source | -26,293Source | -967Source | -1,800Source | 21,802Source | -37,248Source | 877Source | 104,718Source |
| Stockholders' Equity Attributable to ParentUSD | 72,898,298Source | -530,591Source | 153,328,586Source | 80,053,685Source | 5,096,649Source | 167,620,268Source | 85,730,672Source | 6,776,651Source | 172,903,679Source | 94,866,280Source | 10,977,922Source | 21,035,401Source |
| Additional Paid in Capital, Common StockUSD | 202,772,828Source | 81,748,225Source | 331,921,179Source | 197,996,982Source | 81,600,425Source | 326,575,169Source | 193,756,644Source | 78,322,334Source | 315,429,986Source | 189,254,777Source | 77,871,584Source | 68,777,298Source |
| Liabilities and EquityUSD | 79,594,541Source | 4,376,875Source | 163,588,612Source | 88,853,230Source | 8,826,798Source | 173,332,227Source | 94,281,322Source | 11,068,098Source | 181,204,516Source | 98,599,846Source | 14,506,647Source | 24,936,297Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,696,243Source | 4,907,466Source | 10,260,026Source | 8,799,545Source | 3,704,543Source | 5,711,959Source | 8,550,650Source | 4,233,117Source | 8,300,837Source | 3,733,566Source | 3,438,601Source | 3,695,445Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | 152,224Source | — | — | 151,159Source | — | — | 150,095Source | 145,836Source |
| Accounts Payable, CurrentUSD | 620,528Source | 2,529,220Source | 991,720Source | 2,703,554Source | 1,340,538Source | 1,587,305Source | 1,692,051Source | 1,293,755Source | 1,158,054Source | 943,019Source | 646,767Source | 1,151,173Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | 25,606Source | — | — | 58,330Source | — | — | 90,124Source | 205,451Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 3,656,383Source | 2,161,374Source | 9,268,306Source | 3,145,888Source | 2,034,525Source | 4,124,654Source | 3,513,248Source | 2,507,589Source | 4,081,282Source | 2,680,030Source | 2,259,955Source | 2,398,436Source |
| Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 381,784Source | — |
| Other Liabilities, Noncurrent | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 5,559,766Source | 2,042,196Source | 15,309,924Source | 8,140,617Source | 500,148Source | 458,147Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | 0Source | -39,881Source | -70,258Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 429,251Source | 680,824Source | 146,827Source | 271,782Source | -504,406Source | 61,395Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,059,722Source | -4,103,530Source | -27,786,464Source | -19,148,067Source | -18,085,043Source | -17,351,103Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -80,484,587Source | 21,054,342Source | 2,053,130Source | -37,004,201Source | 11,656,666Source | -16,005,708Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 13,399Source | 13,399Source | 0Source | 14,238Source | 243,255Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,897,611Source | 0Source | 108,462,963Source | 103,477,668Source | 8,405,003Source | -204,769Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 38,269,706Source | 913,420Source | 31,206,707Source | 77,742,669Source | 49,573,510Source | 73,441,391Source | 139,220,208Source | 56,490,579Source | 9,165,179Source | 7,188,553Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 973Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,525,206Source | 148,024Source | 5,346,010Source | 4,208,742Source | 5,559,766Source | 2,042,196Source | 15,309,924Source | 8,140,617Source | 500,148Source | 458,147Source |
| Debt Securities, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | 21,802Source | 0Source | 0Source | 0Source |
| DepreciationUSD | — | — | 23,688Source | 6,568Source | 0Source | 24,157Source | 0Source | 12,654Source | 60,499Source | 26,272Source | 177,398Source | 6,723Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | -1,245Source | 2,778Source | -46,461Source | -1,977Source | -48,095Source | 36,281Source | 59,050Source | -38,125Source | -103,841Source | 104,718Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,930,280Source | -5,778,066Source | -19,591,231Source | -9,915,523Source | -16,380,840Source | -13,678,735Source | -48,259,189Source | -27,519,886Source | -19,028,883Source | -18,054,155Source |
| Operating Lease, ExpenseUSD | — | — | 35,934Source | 35,296Source | — | 35,296Source | — | 35,296Source | 118,277Source | 141,182Source | 141,182Source | 56,114Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 2,897,611Source | 0Source | 107,617,495Source | 103,477,668Source | 8,543,559Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 845,468Source | — | 0Source | 44,142Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | 0Source | 260,501Source | 123,440Source |
| Selling, General and Administrative ExpenseUSD | — | — | 5,611,503Source | 1,637,603Source | 7,657,531Source | 5,919,731Source | 7,376,123Source | 5,249,291Source | 23,555,079Source | 11,378,520Source | 6,731,945Source | 6,217,063Source |
| Operating Income (Loss)USD | — | — | -12,768,373Source | -5,827,476Source | -21,050,995Source | -10,832,278Source | -17,841,919Source | -14,598,006Source | -51,974,283Source | -28,589,068Source | -20,089,792Source | -18,128,608Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -48,259Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,930,280Source | -5,778,066Source | -19,591,231Source | -9,915,523Source | -16,380,840Source | -13,678,735Source | -48,259,189Source | -27,519,886Source | -19,028,883Source | -18,054,155Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.13Source | -0.65Source | -0.11Source | -0.11Source | -0.1Source | -0.15Source | -0.49Source | -1.16Source | -3.57Source | -0.72Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.13Source | -0.65Source | -0.11Source | -0.11Source | -0.1Source | -0.15Source | -0.49Source | -1.16Source | -3.57Source | -0.72Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 90,050,973Source | 8,882,570Source | 174,571,543Source | 90,009,625Source | 172,306,932Source | 89,537,171Source | 98,310,190Source | 23,712,220Source | 5,333,096Source | 25,211,726Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 90,050,973Source | 8,882,570Source | 174,571,543Source | 90,009,625Source | 172,306,932Source | 89,537,171Source | 98,310,190Source | 23,712,220Source | 5,333,096Source | 25,211,726Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 12,768,373Source | 5,827,476Source | 21,050,995Source | 10,832,278Source | 17,841,919Source | 14,598,006Source | 51,974,283Source | 28,589,068Source | 20,350,293Source | 18,252,048Source |
| Debt Securities, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | 21,802Source | 0Source | 0Source | 0Source |
| Interest Income (Expense), NetUSD | — | — | 838,093Source | 49,410Source | 1,459,764Source | 916,755Source | 1,461,079Source | 919,271Source | 3,715,094Source | 1,069,182Source | 1,060,909Source | 74,453Source |
| Operating Lease, ExpenseUSD | — | — | 35,934Source | 35,296Source | — | 35,296Source | — | 35,296Source | 118,277Source | 141,182Source | 141,182Source | 56,114Source |
| Research and Development ExpenseUSD | — | — | 7,649,697Source | 4,189,873Source | 13,393,464Source | 5,270,967Source | 10,839,150Source | 10,513,579Source | 29,793,146Source | 17,210,548Source | 13,618,348Source | 12,034,985Source |
Filing attachments
d190975dex991.htm · 8-K · 2026-10-20
Exhibit 99.1 Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors WILMINGTON, Del., October 20, 2026 - Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced the appointment of Scott M. Wasserman, MD, to the Company’s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman’s …
Read attachment ↗d152999dex991.htm · 8-K · 2026-09-08
EX-99.1 2 d152999dex991.htm EX-99.1 EX-99.1 Corporate Overview Exhibit 99.1 Disclaimer This presentation contains information that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Inhibikase Therapeutics, Inc. (the “Company” or “we”) intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in those sections. Generally, we have identified such forwa…
Read attachment ↗d908749dex991.htm · S-8 · 2026-08-11
Exhibit 99.1 INHIBIKASE THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN Section 1. Purpose; Definitions. The purposes of the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan (as amended from time to time, the “Plan”) are to: (a) enable Inhibikase Therapeutics, Inc. (the “Company”) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b) provide those employees, directors and consultants with an incentive for productivity; and (c) prov…
Read attachment ↗d134059dex991.htm · 8-K · 2026-08-11
EX-99.1 2 d134059dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity WILMINGTON, Del., August 11, 2026 - Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and h…
Read attachment ↗d78217dex41.htm · 8-K · 2026-07-29
EX-4.1 2 d78217dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 INHIBIKASE THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2026 Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subject to …
Read attachment ↗d121491dex991.htm · 8-K · 2026-07-23
EX-99.1 2 d121491dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH WILMINGTON, Del., July 23, 2026 - Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to its …
Read attachment ↗